Herborium® Group Inc, Shareholder Update Letter (Part 2)
Herborium Group, Inc. (HBRM) announced key strategies for 2023, emphasizing innovation in healthcare and skincare. The company plans to launch clinically validated hybrid products, including an advanced acne treatment and stem cell-based solutions. Partnerships with leading companies in the US and South Korea aim to enhance product offerings. An AI-driven platform is in the pipeline to transform the business model from a product company to a content and product player. Herborium aims to capitalize on the growing demand for natural healthcare, targeting a market projected to reach USD 347.5 billion by 2029, while focusing on minimizing debt and increasing shareholder value.
- Launch of clinically validated hybrid products, improving margins and consumer appeal.
- Partnerships with US and South Korean companies enhance innovation in skincare.
- Development of an AI-driven platform expected to create new revenue streams.
- Targeting the growing natural healthcare market projected at USD 347.5 billion by 2029.
- Continued focus on minimizing debt, controlling dilution, and increasing profitability.
- None.
Proprietary AI Platform, New Partnerships and New “Natural & Clinical Hybrid” products will drive the value creation in 2023; Further improvement in Cap Table to increase Shareholders valuation
Houston, Texas, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Herborium® Group, Inc. (OTC Pink: HBRM), www.Herborium.com, www.acnease.com a Botanical Therapeutics® Company and the provider of proprietary all botanical medicinal products (Botanical Therapeutics®) and interactive advanced content platform targeting dermatological and other health and wellness concerns, shares a Shareholders Update Letter Part 2 from the CEO, Dr. Agnes Olszewski.
To Our Valued Shareholders
Following last week’s Shareholder Letter Part 1, this Part 2 is to present the major focus for 2023 and beyond. This Plan stems from the analysis of lead market and scientific trends that are reshaping our space, and grounded in previously reported changes and advancements made in 2022.
New Products
One of the most important trends in the healthcare and beauty sectors is the merger of clinical skincare with natural skincare to create clinically validated “hybrid” products that actually work while maintaining their natural ingredient profile.
Herborium’s acne treatment represents such a unique product. We are presently working on the second generation of this clinically validated skincare solution that has a better consumer characteristics (broader application and simpler treatment routine) and improved business profile (increased margins)
The Company is also approaching the most advance science in clinical skincare- stem cell based products. We are working to add two highly innovative products in this category, to our 2023 product portfolio
New Partners
Since Herborium has a well established customer base and strong brand recognition, the most economic and expedient way to access innovative products is partnership with the product originators. We are presently in advanced talks with two companies – one from the US and a second from South Korea that is well known in cosmetic and skin wellness industry for high quality biotechnological applications in skincare.
New Platform
As reported in Part 1 of Shareholders Letter, Herborium already commenced the transformation process from A Product Company to A Content & Product Player in the Sector of Natural Skincare and Wellness. As the demand for natural, safe, and sustainable products is here to stay – the important and challenging advances involve blending natural scientific know-how and traditional medical know how (information) in this field and provide it in a user friendly manner to professionals and end users alike. This creates value added to the customer and additional revenues streams (paid counseling in skincare, beauty, nutrition etc.) for the Company.
We expect to progress aggressively with completing and launching this AI (Artificial Intelligence ) driven platform in 2023
Keeping an Eye on Shareholder Value
By harnessing the growing use of technology and the Company’s perfect fit in a rapidly expending domestic and global market for natural healthcare products (USD166 Billion in 2023; projected USD 347.5 Billion globally in 2029), Herborium® expects to further increase shareholder value. Furthermore, we plan to continue our efforts to minimize debt, control dilution, increase profitability and decrease cost.- all to further improve Corporate’ valuation and shareholder value.
About Herborium Group, Inc.
Herborium Group, Inc. is a botanical therapeutics® company that develops, licenses and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company’s business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
For more information, please visit www.herborium.com, www.acnease.com , www.acnease.fr, and www.acnease.eu
Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.
FAQ
What is Herborium Group's stock symbol?
What new products is Herborium launching in 2023?
What partnerships is Herborium pursuing?
How is Herborium increasing shareholder value?
What market size is Herborium targeting?
